Protection Against Lipopolysaccharide-induced Death by Fluoroquinolones

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Oct 19

PMID 11036044

Citations 18

Authors

A A Khan

T R Slifer

F G Araujo

Y Suzuki

J S Remington

Affiliations

Soon will be listed here.

Abstract

Because fluoroquinolones have an immunomodulatory effect on cytokine production by lipopolysaccharide (LPS)-treated human monocytes, we examined the effect of fluoroquinolones on the survival of mice injected with a lethal dose of LPS. Trovafloxacin (100 mg/kg), ciprofloxacin (250 mg/kg), and tosufloxacin (100 mg/kg) protected 75% (P = 0.0001), 25% (P = 0.002), and 50% (P = 0.002), respectively, of mice against death. The fluoroquinolones significantly reduced serum levels of interleukin-6 and tumor necrosis factor alpha in LPS-treated mice. The protective effects of fluoroquinolones in LPS-induced shock in mice may also occur in humans.

Citing Articles

Exploring the Therapeutic Potential of Antibiotics in Hyperglycemia-Induced Macrophage Dysfunctions.

Yossapol M, Srinontong P, Aengwanich W, Panil M, Somsup S, Odoi J Antibiotics (Basel). 2025; 14(2).

PMID: 40001441 PMC: 11851781. DOI: 10.3390/antibiotics14020198.

Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice.

Hara R, Taguchi K, Ogino H, Okamoto Y, Enoki Y, Kizu J J Pharm Health Care Sci. 2024; 10(1):68.

PMID: 39491012 PMC: 11533349. DOI: 10.1186/s40780-024-00392-4.

Immunomodulatory Effects and Protection in Sepsis by the Antibiotic Moxifloxacin.

Velho T, Raquel H, Figueiredo N, Neves-Costa A, Pedroso D, Santos I Antibiotics (Basel). 2024; 13(8).

PMID: 39200042 PMC: 11350752. DOI: 10.3390/antibiotics13080742.

Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome.

Yudhawati R, Wicaksono N Biomedicines. 2024; 12(4).

PMID: 38672119 PMC: 11048665. DOI: 10.3390/biomedicines12040761.

Pleiotropic effects of antibiotics on T cell metabolism and T cell-mediated immunity.

Franz T, Negele J, Bruno P, Bottcher M, Mitchell-Flack M, Reemts L Front Microbiol. 2022; 13:975436.

PMID: 36329851 PMC: 9623020. DOI: 10.3389/fmicb.2022.975436.

References

Dinarello C . Interleukin-1. Rev Infect Dis. 1984; 6(1):51-95. DOI: 10.1093/clinids/6.1.51. View

Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts C, Wretlind B . Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis. 1995; 172(1):296-301. DOI: 10.1093/infdis/172.1.296. View

Bone R, Fisher Jr C, Clemmer T, Slotman G, Metz C, Balk R . A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987; 317(11):653-8. DOI: 10.1056/NEJM198709103171101. View

Beutler B, Cerami A . Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988; 57:505-18. DOI: 10.1146/annurev.bi.57.070188.002445. View

Butler L, Layman N, Cain R, Riedl P, Mohler K, Bobbitt J . Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol. 1989; 53(3):400-21. DOI: 10.1016/0090-1229(89)90003-2. View

Ziegler E, Fisher Jr C, Sprung C, Straube R, Sadoff J, Foulke G . Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991; 324(7):429-36. DOI: 10.1056/NEJM199102143240701. View

Anderson B, Bensard D, Harken A . The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet. 1991; 172(5):415-24. View

Bailly S, Fay M, Ferrua B, Gougerot-Pocidalo M . Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha. Clin Exp Immunol. 1991; 85(2):331-4. PMC: 1535757. DOI: 10.1111/j.1365-2249.1991.tb05728.x. View

Shalit I . Immunological aspects of new quinolones. Eur J Clin Microbiol Infect Dis. 1991; 10(4):262-6. DOI: 10.1007/BF01966999. View

10.

Greenman R, Schein R, Martin M, Wenzel R, Macintyre N, Emmanuel G . A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991; 266(8):1097-102. View

11.

Parrillo J . Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328(20):1471-7. DOI: 10.1056/NEJM199305203282008. View

12.

Cohen J, Carlet J . INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996; 24(9):1431-40. DOI: 10.1097/00003246-199609000-00002. View

13.

van der Poll T, de Waal Malefyt R, Coyle S, Lowry S . Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis. 1997; 175(1):118-22. DOI: 10.1093/infdis/175.1.118. View

14.

Damas P, Canivet J, De Groote D, Vrindts Y, Albert A, Franchimont P . Sepsis and serum cytokine concentrations. Crit Care Med. 1997; 25(3):405-12. DOI: 10.1097/00003246-199703000-00006. View

15.

Mayeux P . Pathobiology of lipopolysaccharide. J Toxicol Environ Health. 1997; 51(5):415-35. DOI: 10.1080/00984109708984034. View

16.

Khan A, Slifer T, Remington J . Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother. 1998; 42(7):1713-7. PMC: 105671. DOI: 10.1128/AAC.42.7.1713. View

17.

Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R . Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 1998; 351(9107):929-33. View

18.

Fisher Jr C, Dhainaut J, Opal S, Pribble J, Balk R, Slotman G . Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994; 271(23):1836-43. View

19.

Dhainaut J, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet J, Wolff M . Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994; 22(11):1720-8. View

20.

Bone R, Balk R, Fein A, Perl T, Wenzel R, Reines H . A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. 1995; 23(6):994-1006. DOI: 10.1097/00003246-199506000-00003. View